<DOC>
	<DOCNO>NCT01447134</DOCNO>
	<brief_summary>1 . Primary endpoint ( ) : To determine relationship drug distribution angiogenesis head neck cancer patient . 2 . Secondary endpoint ( ) : To expand safety database [ F-18 ] RGD-K5 correlate parameter image study clinical treatment response prognosis .</brief_summary>
	<brief_title>RGD-K5 Head Neck Cancer Patients</brief_title>
	<detailed_description>This uncontrolled , open-labeled , non-randomized , prospective study . The study duration expect complete period 3 year . Up 100 patient would include . Group A would undergo surgical excision biopsy ( n=20 ) ; Group B would N2c-3M0 disease receive chemotherapy follow concurrent chemoradiotherapy ( n=40 ) ; Group C would M1 disease receive biotherapy chemotherapy ( n=40 ) . Group A patient could include Group B C qualify . Each participant must fulfill inclusion exclusion criterion .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Head neck cancer patient ( include nasopharyngeal cancer ) Age equal 20 year old Referred Chang Gung Memorial Hospital ( CGMH ) Head Neck Oncology team . Willing sign inform consent Patient pregnant lactating ; Patients concomitant previous 2nd primary cancer head neck malignancy ; Unable tolerate MR PET/CT scan , magnetic implant ( e.g . receive intracranial aneurysm surgery , cardiac pacemaker , artificial valve replacement , artificial ear ) , poor blood sugar control ( fast sugar 200 mg/dl ) , claustrophobia , unable lie still . Unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>